Articles Tập 67 Số CĐ1-NCKH 27/01/2026

TREATMENT OUTCOMES OF PHARMACOLOGICAL CLOSURE OF PATENT DUCTUS ARTERIOSUS IN PRETERM INFANTS AT THE NATIONAL HOSPITAL OF OBSTETRICS AND GYNECOLOGY

Ha Thi Luong1,2, Tran Thi Hoa1,2
1 Neonatal Center, National Hospital of Obstetrics and Gynecology
2 Trung tâm Sơ sinh, Bệnh viện Phụ Sản Trung ương
DOI: 10.52163/yhc.v67iCD1.4216
34 Views
25 Downloads
Keywords
Patent ductus arteriosus, hemodynamically significant patent ductus arteriosus, Ibuprofen, Paracetamol, preterm infants.
Abstract

Objective: To determine the incidence of patent ductus arteriosus in preterm infants and to evaluate the effectiveness of pharmacological closure of the ductus arteriosus in preterm neonates at the National Hospital of Obstetrics and Gynecology.

Method: This retrospective and prospective descriptive study included 267 preterm infants born at < 32 weeks’ gestation admitted to the Neonatal Center, National Hospital of Obstetrics and Gynecology. All infants underwent routine echocardiography on days 3-4 after birth or earlier if patent ductus arteriosus was suspected. Infants were classified into three groups: closed ductus, patent ductus arteriosus without hemodynamic significance, and hemodynamically significant patent ductus arteriosus. Infants with hemodynamic significant patent ductus arteriosus received Ibuprofen or Paracetamol for medical closure. The study assessed the efficacy of both drugs, as well as changes in clinical and echocardiographic parameters before and after treatment, and evaluated complications associated with hemodynamic significant patent ductus arteriosus.

Results: Patent ductus arteriosus was diagnosed in 61.4%, including 28.7% of hemodynamic significant patent ductus arteriosus, birth weight < 1000g (63.8%) and gestational age < 28 weeks  (55.3%). Among those, 89.4% infants received pharmacological treatment, with successful ductal closure achieved in 69%. The success rates were 54.2% for Paracetamol and 64% for Ibuprofen. Clinical symptoms improved markedly after treatment. The mean ductal diameter decreased from 2.73 ± 0.65 mm before treatment to 1.09 ± 1.22 mm after treatment, and the LA/Ao ratio decreased from 1.87 ± 0.39 to 1.42 ± 0.33. Neonatal sepsis increases the risk of hemodynamic significant patent ductus arteriosus by approximately sixtimes. Infants with hemodynamic significant patent ductus arteriosus had higher rates of pulmonary hemorrhage, sepsis, intraventricular hemorrhage, and bronchopulmonary dysplasia compared with those without hemodynamic significant patent ductus arteriosus.

Conclusions: Pharmacological treatment hemodynamic significant patent ductus arteriosus with Ibuprofen or Paracetamol is effective in achieving patent ductus arteriosus closure in preterm infants. Treatment reduces clinical symptoms as well as reduces ultrasound parameters. Hemodynamic significant patent ductus arteriosus is associated with an increased risk of severe complications, so routine echocardiography is required in preterm infants, especially extremely preterm infants.

References
[1]
West Midlands Neonatal Operational Delivery Network, Bedside Clinical Guidelines Partnership. Patent ductus arteriosus. In: Neonatal guidelines 2022-2024, issue 9. Stoke-on-Trent: University Hospital of North Midlands NHS Trust, 2022, p. 309-312. Google Scholar
[2]
Conrad C, Newberry D. Understanding the pathophysiology, implications, and treatment options of patent ductus arteriosus in the neonatal population. Adv Neonatal Care, 2019, 19 (3): 179-187. doi: 10.1097/ANC.0000000000000590. Google Scholar
[3]
Lissauer T, Fanaroff A.A et al. Patent ductus arteriosus (PDA). In: Neonatology at a glance. 4th ed. Chichester (West Sussex): Wiley-Blackwell, 2020, p. 84-5. Google Scholar
[4]
Hoffman J.I.E. Patent ductus arteriosus. In: The natural and unnatural history of congenital heart disease. Oxford: Blackwell Publishing, 2009, p. 79-92. Google Scholar
[5]
Aranda J.V, Thomas R. Systematic review: intravenous ibuprofen in preterm newborns. Semin Perinatol, 2006, 30 (3): 114-120. doi: 10.1053/j.semperi.2006.04.003. Google Scholar
[6]
Dani C, Poggi C et al. Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized controlled trial. Trials, 2016, 17: 182. doi: 10.1186/s13063-016-1294-4. Google Scholar
[7]
Miall S, Hensey A et al. Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial protocol (SMART-PDA). BMJ Open, 2024, 14 (7): e087998. doi:10.1136/bmjopen-2024-087998. Google Scholar
[8]
Benitz W.E. Patent ductus arteriosus in preterm infants. Pediatrics, 2016, 137 (1): e20153730. doi: 10.1542/peds.2015-3730 Google Scholar
[9]
Huỳnh Thị Lệ, Phan Hùng Việt, Phạm Hữu Hòa. Đặc điểm lâm sàng và siêu âm Doppler tim của còn ống động mạch ở trẻ sơ sinh non tháng tại Khoa Nhi, Bệnh viện Trung ương Huế. Tạp chí Y Dược học, Trường Đại học Y Dược Huế, 2011, 6: 30. doi: 10.34071/jmp.2011.6.3. Google Scholar
[10]
Nguyễn Cao Minh Uyên, Nguyễn Thanh Thiện và cộng sự. Đặc điểm lâm sàng và kết quả điều trị tồn tại ống động mạch ở trẻ sinh non ≤ 28 tuần tại Khoa Hồi sức sơ sinh, Bệnh viện Nhi Đồng 2. Tạp chí Y học Việt Nam, 2023, 520 (1B): 141-147. doi: 10.51298/vmj.v520i1B.3856 Google Scholar
[11]
Abushanab D, Rouf P.A et al. Cost-effectiveness of oral versus intravenous Ibuprofen therapy in preterm infants with patent ductus arteriosus in the neonatal intensive care setting: A cohort-based study. Clin Ther, 2021, 43 (2): 336-348.e7. doi: 10.1016/j.clinthera.2020.12.004 Google Scholar
[12]
Nguyễn Phan Minh Nhật, Vũ Minh Phúc, Nguyễn Thu Tịnh. Hiệu quả đóng ống động mạch bằng Paracetamol ở trẻ sơ sinh non tháng. Tạp chí Y học thành phố Hồ Chí Minh, 2019, 23 (1): 97-103. Google Scholar
[13]
Navikienė J, Liubšys A et al. Impact of medical treatment of hemodynamically significant patent ductus arteriosus on cerebral and renal tissue oxygenation measured by near-infrared spectroscopy in very low-birth-weight infants. Medicina (Kaunas) , 2022, 58 (4): 475. doi: 10.3390/medicina58040475 Google Scholar
[14]
Liu C, Zhu X et al. Related factors of patent ductus arteriosus in preterm infants: A systematic review and meta-analysis. Front Pediatr, 2021, 8: 605879. doi: 10.3389/fped.2020.605879 Google Scholar
[15]
Su B.H, Lin H.Y et al. Therapeutic strategy of patent ductus arteriosus in extremely preterm infants. Pediatr Neonatol, 2020, 61 (2): 133-141. doi: 10.1016/j.pedneo.2019.10.002 Google Scholar